MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

Omeros Corp

Geschlossen

BrancheGesundheitswesen

3.08 -2.53

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.99

Max

3.16

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.1M

-33M

Verkäufe

412K

412K

Gewinnspanne

-8,121.359

Angestellte

202

EBITDA

-1.9M

-35M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+181.25% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-246M

176M

Vorheriger Eröffnungskurs

5.61

Vorheriger Schlusskurs

3.08

Nachrichtenstimmung

By Acuity

55%

45%

309 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Omeros Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Juli 2025, 15:29 UTC

Wichtige Markttreiber

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7. Juli 2025, 23:44 UTC

Market Talk

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7. Juli 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Juli 2025, 23:41 UTC

Market Talk

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7. Juli 2025, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Juli 2025, 23:19 UTC

Market Talk

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7. Juli 2025, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Juli 2025, 22:20 UTC

Market Talk

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7. Juli 2025, 21:34 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Juli 2025, 20:45 UTC

Akquisitionen, Fusionen, Übernahmen

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. Juli 2025, 20:16 UTC

Market Talk

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7. Juli 2025, 19:37 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7. Juli 2025, 19:12 UTC

Market Talk

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7. Juli 2025, 18:33 UTC

Market Talk

Gold Flat as Investors Assess Market Direction -- Market Talk

7. Juli 2025, 18:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Juli 2025, 16:53 UTC

Ergebnisse

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7. Juli 2025, 16:30 UTC

Market Talk

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Juli 2025, 16:05 UTC

Akquisitionen, Fusionen, Übernahmen

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7. Juli 2025, 15:41 UTC

Market Talk

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7. Juli 2025, 15:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. Juli 2025, 15:40 UTC

Market Talk

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7. Juli 2025, 15:30 UTC

Market Talk

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7. Juli 2025, 15:18 UTC

Market Talk

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7. Juli 2025, 15:14 UTC

Akquisitionen, Fusionen, Übernahmen

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7. Juli 2025, 15:00 UTC

Akquisitionen, Fusionen, Übernahmen

GSK Completes Acquisition of Efimosfermin

7. Juli 2025, 14:52 UTC

Market Talk

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7. Juli 2025, 14:51 UTC

Market Talk

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7. Juli 2025, 14:45 UTC

Market Talk

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Peer-Vergleich

Kursveränderung

Omeros Corp Prognose

Kursziel

By TipRanks

181.25% Vorteil

12-Monats-Prognose

Durchschnitt 9 USD  181.25%

Hoch 9 USD

Tief 9 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Omeros Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

6.265 / 7.49Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

309 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.